MBX Biosciences is trading at $61.50 (-6.41%) today as the stock undergoes a sharp pullback following a recent rally tied to clinical data.
- The stock's earlier gains were driven by favorable one-year data for canvuparatide in chronic hypoparathyroidism, which confirmed sustained efficacy.
- Management remains on track to initiate Phase 3 clinical trials for the candidate in Q3 2026.
- Today's decline appears to be driven by post-news volatility and a reversal of recent momentum rather than a new company-specific announcement.